The Opportunistic Arbitrage model gained a solid 21.4% in February versus 4.1% for the benchmark S&P 500.
SVNT
4 posts
Manager: Mark Holder Model: Opportunistic Arbitrage Disclosure: Long PUDA, LIWA, NUVA, RIGL, SVNT, AER, LIZ, X, LLNW as of time of writing This model had a difficult month in April as it underperformed the S&P 500 by a disappointing margin: down 1.6% versus a 2.85% gain for the index. The […]
silver, which seemed to lead other commodities down as well. While I’m not sure this is yet a contrarian perspective, I hold the view that this is an
Limiting portfolio sizes to 20-30 stocks allows for diversification without getting to levels of diworstification. Hence, I have always had a few 'risky' biotech stocks. Based on the results of Savient Pharma (SVNT) the rewards have clearly outweighed the risks. Additionally, Rigel Pharma (RIGL) and Cephalon (CEPH) have seen bullish trading of late. Not being predisposed to investing in this sector, I just found the valuations too compelling.